Immune Profile of Gastric Cancers with Expression of Programmed Death Receptor Ligand-1

被引：0
|
作者：
Abate, Miseker E. [1 ]
Lin, Ya-Hui [1 ]
Strong, Vivian [1 ]
Vardhana, Santosh [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
ANNALS OF SURGICAL ONCOLOGY | 2022年 / 29卷 / SUPPL 2期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
E203
引用
收藏
页码：487 / 488
页数：2
相关论文
共 50 条
  • [1] Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma
    Yu Wei-Bo
    Rao Jian-Yu
    [J]. 慢性疾病与转化医学(英文), 2019, 5 (03) : 170 - 177
  • [2] Chemotherapy induces alteration of programmed death ligand-1 expression in gastric cancer
    Yamashita, Kohei
    Iwatsuki, Masaaki
    Iwagami, Shiro
    Eto, Kojiro
    Koga, Yuki
    Kiyozumi, Yuki
    Baba, Yoshifumi
    Yoshida, Naoya
    Baba, Hideo
    [J]. CANCER RESEARCH, 2019, 79 (13)
  • [3] Expression patterns of programmed death-1 and programmed death-1 ligand-1 on T cells in gastric cancer
    Kim, Ji-Hyun
    Kim, Shinn-Young
    Shin, Eun-Young
    Jung, Ji-Han
    Choi, Hyun-Joo
    Jun, Kyong-Hwa
    [J]. ONCOLOGY LETTERS, 2019, 18 (03) : 2661 - 2669
  • [4] Programmed death ligand-1 and MET co-expression is a poor prognostic factor in gastric cancers after resection
    Kwon, Mi Jung
    Kim, Kab-Choong
    Nam, Eun Sook
    Cho, Seong Jin
    Park, Hye-Rim
    Min, Soo Kee
    Seo, Jinwon
    Choe, Ji-Young
    Lee, Hye Kyung
    Kang, Ho Suk
    Min, Kyueng-Whan
    [J]. ONCOTARGET, 2017, 8 (47) : 82399 - 82414
  • [5] Androgen Receptor Transcriptionally Inhibits Programmed Death Ligand-1 Expression and Influences Immune Escape in Bladder Cancer
    Sun, Anran
    Luo, Yu
    Xiao, Wen
    Zhu, Zhipeng
    Yan, Hongyu
    Miao, Chaohao
    Zhang, Wenzhao
    Bai, Peide
    Liu, Chenfeng
    Yang, Dianqiang
    Shao, Zhiqiang
    Song, Jing
    Wu, Zhun
    Chen, Bin
    Xing, Jinchun
    Wang, Tao
    [J]. LABORATORY INVESTIGATION, 2023, 103 (07)
  • [6] Antagonizing programmed death-1 and programmed death ligand-1 as a therapeutic approach for gastric cancer
    Liu, Xiaojun
    Yang, Zhongxia
    Latchoumanin, Olivier
    Qiao, Liang
    [J]. THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2016, 9 (06): : 853 - 860
  • [7] Inhibition of Programmed Death Receptor-1/Programmed Death Ligand-1 Interactions by Ginsenoside Metabolites
    Yim, Nam-Hui
    Kim, Young Soo
    Chung, Hwan-Suck
    [J]. MOLECULES, 2020, 25 (09):
  • [8] The association of programmed death ligand-1 expression with MMR, and EBV status in gastric carcinoma in Oman
    Al-Amri, F.
    Shalaby, A.
    ALMasqari, M.
    [J]. HISTOPATHOLOGY, 2022, 81 : 64 - 65
  • [9] Expression of programmed death ligand-1 and programmed death 1 in hepatocellular carcinoma and its clinical significance
    Long, J.
    Qu, Tao
    Pan, X. F.
    Tang, X.
    Wan, H. H.
    Qiu, P.
    Xu, Yan-Hua
    [J]. JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2018, 14 : S1188 - S1192
  • [10] Drug of the year: Programmed Death-1 receptor/Programmed Death-1 Ligand-1 receptor monoclonal antibodies
    Robert, Caroline
    Soria, Jean-Charles
    Eggermont, Alexander M. M.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 (14) : 2968 - 2971
12345